Moxetumomab pasudotox
Modify Date: 2024-04-05 21:13:45
Moxetumomab pasudotox structure
|
Common Name | Moxetumomab pasudotox | ||
|---|---|---|---|---|
| CAS Number | 1020748-57-5 | Molecular Weight | 63.5 (kDa) | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Moxetumomab pasudotoxMoxetumomab pasudotox (CAT 8015) is anti-CD22 immunotoxin containing an anti-CD22 Fv and Pseudomonas exotoxin. CD22 is a cell surface receptor expressed on a variety of malignant B-cells. Moxetumomab pasudotox can be used in the research of hairy cell leukemia (HCL)[1][2][3]. |
| Name | Moxetumomab pasudotox |
|---|
| Description | Moxetumomab pasudotox (CAT 8015) is anti-CD22 immunotoxin containing an anti-CD22 Fv and Pseudomonas exotoxin. CD22 is a cell surface receptor expressed on a variety of malignant B-cells. Moxetumomab pasudotox can be used in the research of hairy cell leukemia (HCL)[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vitro | Moxetumomab pasudotox (0-10 mg/mL, 66 h) reduces cell viability of BCP-ALL cells (determined by Annexin-V negative)[3]. The binding and internalization of MP/CD22 complexes is correlated with pre-B ALL cell line responses to MP[5]. |
| In Vivo | Moxetumomab pasudotox (300 mg/kg, i.v., every other day) prolongs median survival in 697 cell model (P < 0.0001)[3]. Moxetumomab pasudotox (0.4 mg/kg, i.v. three doses, every other day) clears the bone marrow (BM) from acute lymphoblastic leukemia (ALL), but disease relapses from discrete BM-sites in NSG mouse model[4]. Animal Model: NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mouse model[4] Dosage: 0.4 mg/kg Administration: Intravenous injection (i.v.), three doses, every other day. Result: Survived much longer but died from ALL after 40 d. Reduced BM-infiltration to 4% on day 8. |
| References |
[2]. hillon S. Moxetumomab Pasudotox: First Global Approval. Drugs. 2018 Nov;78(16):1763-1767. |
| Molecular Weight | 63.5 (kDa) |
|---|